基于可变剪接的乳腺癌患者预后特征分析
Analysis of Prognostic Associated Alternative Splicing Signatures in Breast Cancer
摘要: 本文在对传统临床数据分析的基础上,引入可变剪接数据,运用单因素COX回归、Lasso回归等方法筛选得到与生存显著相关的可变剪接事件,研究了影响乳腺癌患者总生存率的关键因素,构造了较为理想的10-可变剪接事件预后模型,挖掘了可变剪接事件与乳腺癌预后的关联性。结果表明,可变剪接事件可以作为独立预后因子,较好地预测乳腺癌患者的生存情况,这为医学人员进一步认识与理解乳腺癌的预后特征提供了理论依据和数据支撑,也为进一步实验验证提供了潜在目标。
Abstract: Based on the analysis of traditional clinical data, this paper introduces alternative splicing events, and survival-associated alternative splicing events were selected by using univariate COX regression analysis and Lasso regression analysis. Then, we study the key factors affecting the overall survival rate of breast cancer patients, construct the prognosis model of 10-survival-associated alternative splicing events, and excavate the correlation between alternative splicing events and prognosis of breast cancer patients. The results show that alternative splicing events can be used as an independent prognostic factor to predict the survival of breast cancer patients. It is a theoretical basis and data support for medical personnel to further understand the prognostic characteristics of breast cancer, and also a potential target for further experimental verification.
文章引用:姜蔚. 基于可变剪接的乳腺癌患者预后特征分析[J]. 统计学与应用, 2021, 10(3): 355-364. https://doi.org/10.12677/SA.2021.103035

参考文献

[1] El-Serag, H.B. and Rudolph, K.L. (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 132, 2557-2576.
[Google Scholar] [CrossRef] [PubMed]
[2] Mikulits, W. (2018) Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma. Future Oncology, 5, 1169.
[Google Scholar] [CrossRef] [PubMed]
[3] Fu, X.D. and Ares, M. (2014) Context-Dependent Control of Alternative Splicing by RNA-Binding Proteins. Nature Reviews Genetics, 15, 689-701.
[Google Scholar] [CrossRef] [PubMed]
[4] Song, X., Zeng, Z., Wei, H., et al. (2017) Alternative Splicing in Cancers: From Aberrant Regulation to New Therapeutics. Seminars in Cell & Developmental Biology, 75, 13-22.
[Google Scholar] [CrossRef] [PubMed]
[5] Li, Y., Sun, N., Lu, Z., et al. (2017) Prognostic Alternative mRNA Splicing Signature in Non-Small Cell Lung Cancer. Cancer Letters, 393, 40-51.
[Google Scholar] [CrossRef] [PubMed]
[6] 刘文斌, 王兵, 方刚, 石晓龙, 许鹏. 基于中值的JS散度可变剪接差异分析研究[J]. 电子与信息学报, 2020, 42(6): 1392-1400.
[7] Park, E., Pan, Z., Zhang, Z., et al. (2018) The Expanding Landscape of Alternative Splicing Variation in Human Populations. American Journal of Human Genetics, 102, 11-26.
[Google Scholar] [CrossRef] [PubMed]
[8] Lin, J.C. (2018) Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment. International Journal of Molecular Sciences, 19, 75.
[Google Scholar] [CrossRef] [PubMed]
[9] Martinez-Montiel, N., Rosas-Murrieta, N.H., Ruiz, M.A., et al. (2018) Alternative Splicing as a Target for Cancer Treatment. International Journal of Molecular Sciences, 19, 545.
[Google Scholar] [CrossRef] [PubMed]
[10] 王科俊, 吕俊杰, 冯伟兴, 等. 可变剪接与疾病的生物信息学研究概况[J]. 生命科学研究, 2011, 15(1): 86-94.
[11] Mauger, E.A., Wolfe, R.A. and Port, F.K. (1995) Transient Effects in the Cox Proportional Hazards Regression Model. Statistics in Medicine, 14, 1553-1565.
[Google Scholar] [CrossRef] [PubMed]
[12] Wang, E.T., Sandberg, R., Luo, S.J., et al. (2008) Alternative Isoform Regulation in Human Tissue Transcriptomes. Nature, 456, 470-476.
[Google Scholar] [CrossRef] [PubMed]